MediciNova is planning to launch a Phase 3 clinical trial that will evaluate its investigational oral candidate ibudilast (MN-166) in people with secondary progressive multiple sclerosis (SPMS) without relapses. The company is actively engaging with potential partners that could help fund the study. “Over the past quarter, we…

A non-invasive retina imaging technique known as optical coherence tomography (OCT) provided evidence of the neuroprotective effect of ibudilast (MN-166) — an oral medication designed to reduce the body’s inflammatory responses —  in people with progressive forms of multiple sclerosis (MS). The data also…

A Phase 3 trial is planned to confirm the safety and efficacy of oral ibudilast (MN-166) in treating people with secondary progressive multiple sclerosis (SPMS) without relapses, or those whose disease is not active, MediciNova announced. Data from this single Phase 3 study may be used to request…

MediciNova will present data from its clinical trial of ibudilast (MN-166) in progressive multiple sclerosis (MS) at the upcoming 7th Joint ECTRIMS – ACTRIMS Meeting in Paris. The European and American Committees for Treatment and Research in Multiple Sclerosis (ECTRIMS and ACTRIMS) selected the presentation “…

Ibudilast (MN-166) has shown enough promise as a treatment for progressive multiple sclerosis (MS) that its U.S. Phase 2b trial (NCT01982942) should continue, the U.S. National Institute of Health’s Data and Safety Monitoring Board has recommended. A key goal of the 96-week trial is to determine whether ibudilast can slow the…

MediciNova recently reported that half of the 255 patients enrolled in a Phase 2b clinical trial (SPRINT-MS) exploring MN-166 (ibudilast) in progressive multiple sclerosis (MS) had completed the 96-week-long treatment. Interim data will be analyzed by the trial’s external Data Safety Monitoring Board later this year, with results…

MediciNova recently reported that half of the 255 patients enrolled in a Phase 2b clinical trial (SPRINT-MS) exploring MN-166 (ibudilast) in progressive multiple sclerosis (MS) had completed the 96-week-long treatment. Interim data will be analyzed by the trial’s external Data Safety Monitoring Board later this year, with results…

MediciNova, Inc., announced that MN-166 (ibudilast) has been approved for “fast track” development by the U.S. Food and Drug Administration (FDA) as a potential treatment for progressive multiple sclerosis (MS). Progressive MS includes both the primary progressive (PPMS) and secondary progressive (SPMS) forms of the disease. MediciNova’s MN-166 was licensed from Kyorin Pharmaceuticals for its potential…

MediciNova, Inc., a biopharmaceutical company focused on acquiring and developing novel, small-molecule therapeutics for the treatment of diseases with unmet medical needs, recently announced that the ongoing clinical trial of MN-166 (ibudilast) in patients with progressive multiple sclerosis (progressive MS) has finished the randomization of 255 patients, exceeding the…

While multiple sclerosis (MS) is considered a rare condition with major unmet medical needs, the treatments for progressive forms of MS are even scarcer, with no viable, FDA-approved drugs available to specifically address these forms of the disease. Because of this, the MS community is eagerly following a major…

MediciNova, Inc., a publicly-traded biopharmaceutical company developing novel, small-molecule therapeutics for the treatment of diseases with unmet medical needs, recently announced that the National Institute of Neurological Disorders and Stroke (NINDS) notified the company of full enrollment of their ongoing clinical study evaluating ibudilast (MN-166) for the treatment of progressive…

MediciNova, Inc., has announced the acceptance of an abstract describing their ongoing Phase 2b clinical trial of MN-166 (ibudilast) in progressive multiple sclerosis (MS). The poster is to be presented at the American Academy of Neurology (AAN) 67th Annual Meeting, April 18 – 25, 2015 in Washington, DC. The presentation is titled…

MediciNova, Inc., recently announced that it had surpassed 50% enrollment for the phase 2b clinical trial evaluating MN-166 (ibudilast) in progressive multiple sclerosis patients. As of September 15th, 150 of an expected 250 patients have enrolled for treatment, and the trial is on track to complete enrollment by the…